Resources

Chris Molloy on new pension scale-up fund news, member news from Touchlight, the major GSK investment in Cambridge, a valuable collaboration for Relation and BIA's parliamentary engagement

Touchlight announced the first UK patient was dosed with a bespoke cancer vaccine manufactured using its proprietary dbDNA technology.

tranScrip recently hosted its Ask the Experts Live Q&A: From Preclinical to First-in-Human. If you couldn't join us live, the full recording is now available to watch on demand at your convenience.

How to unlock the UK's innovative life sciences and biotech potential

Chris Molloy on scale-up policy, improving treatments pipeline, LSSP, GMM regulation, LLSW, MDUK's Pedal Paddle Peak and Dr Sally Ann Forsyth OBE

The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.

Microbiotica announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial.

Poolbeg will present data on POLB 001 at the European Hematology Association Congress (EHA), taking place 11-14 June 2026 in Stockholm, Sweden.

It has been an extremely challenging time for biotech post COVID-19 boom, but our Q1 financing report offers hope with continued positive momentum.

Epitopea announced that it has received approval from MHRA and the REC for its clinical trial application (CTA) for its first-in-human clinical trial (OVACT) of CryptiVax™-1001.

The UK BioIndustry Association (BIA) is the UK’s trade association for innovative life sciences and the leading UK-wide forum for expert communities and high quality peer-to-peer networking in the sector.

Sonjoy Brahma, tranScrip’s VP of Clinical Operations, joins Joab Williamson of Faron Pharmaceuticals to unpack the operational realities of life in a small emerging biotech. They’ll explore the pressures of rare oncology development, how cash runway and clinical milestones shape decision-making and why flexibility, external expertise and careful planning are essential to moving programmes forward with confidence.

EnteroBiotix has completed enrolment in the Phase 2a MAST trial of EBX-102-02, investigating intestinal microbiota transplant prior to allogeneic stem cell transplantation in patients with haematological malignancies.

Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025, the European Union’s flagship research and innovation funding programme.

A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.

Microbiotica announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.

The Cell and Gene Therapy Catapult (CGT Catapult) has published new insights into the UK’s CGT clinical trials in its 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.

Brainomix has been selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD).

AAVantgarde Bio, a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has announced the completion of enrollment in LUCE-1.

EnteroBiotix Limited announced positive final results from for EBX-102-02, a therapeutic for irritable bowel syndrome with constipation and diarrhoea.